

By Senator Brodeur

10-00822D-23

20231550\_\_

1                                   A bill to be entitled  
2       An act relating to prescription drugs; providing a  
3       short title; amending s. 499.005, F.S.; specifying  
4       additional prohibited acts related to the Florida Drug  
5       and Cosmetic Act; amending s. 499.012, F.S.; providing  
6       that prescription drug manufacturer and nonresident  
7       prescription drug manufacturer permitholders are  
8       subject to specified requirements; creating s.  
9       499.026, F.S.; defining terms; requiring certain drug  
10      manufacturers to notify the Department of Business and  
11      Professional Regulation of reportable drug price  
12      increases on a specified form on the effective date of  
13      such increase; providing requirements for the form;  
14      providing construction; requiring such manufacturers  
15      to submit certain reports to the department by a  
16      specified date each year; providing requirements for  
17      the reports; authorizing the department to request  
18      certain additional information from the manufacturer  
19      before approving the report; requiring the department  
20      to submit the forms and reports to the Agency for  
21      Health Care Administration to be posted on the  
22      agency's website; prohibiting manufacturers from  
23      claiming a public records exemption for trade secrets  
24      for any information provided in such notifications or  
25      reports; providing that department employees remain  
26      protected from liability for releasing the forms and  
27      reports as public records; authorizing the department,  
28      in consultation with the agency, to adopt rules;  
29      providing for emergency rulemaking; amending s.

10-00822D-23

20231550\_\_

30 624.307, F.S.; requiring the Division of Consumer  
31 Services of the Department of Financial Services to  
32 designate an employee as the primary contact for  
33 consumer complaints involving pharmacy benefit  
34 managers; requiring the division to refer certain  
35 complaints to the Office of Insurance Regulation;  
36 amending s. 624.490, F.S.; revising the definition of  
37 the term "pharmacy benefit manager"; amending s.  
38 626.88, F.S.; revising the definition of the term  
39 "administrator"; defining the term "pharmacy benefit  
40 manager"; amending s. 626.8805, F.S.; providing a  
41 grandfathering provision for certain pharmacy benefit  
42 managers operating as administrators; providing a  
43 penalty for certain persons who do not hold a  
44 certificate of authority to act as an administrator on  
45 or after a specified date; providing additional  
46 requirements for pharmacy benefit managers applying  
47 for a certificate of authority to act as an  
48 administrator; exempting pharmacy benefit managers for  
49 certain fees; amending s. 626.8814, F.S.; requiring  
50 pharmacy benefit managers to identify certain  
51 ownership affiliations to the office; requiring  
52 pharmacy benefit managers to report any change in such  
53 information to the office within a specified  
54 timeframe; creating s. 626.8825, F.S.; defining terms;  
55 providing requirements for certain contracts between a  
56 pharmacy benefit manager and a pharmacy benefits plan  
57 or program or a participating pharmacy; specifying  
58 requirements for certain administrative appeal

10-00822D-23

20231550\_\_

59 procedures that such contracts with participating  
60 pharmacies must include; requiring pharmacy benefit  
61 managers to submit reports on submitted appeals to the  
62 office every 90 days; creating s. 626.8827, F.S.;  
63 specifying prohibited practices for pharmacy benefit  
64 managers; creating s. 626.8828, F.S.; authorizing the  
65 office to investigate administrators that are pharmacy  
66 benefit managers and certain applicants; requiring the  
67 office to review certain referrals and investigate  
68 them under certain circumstances; providing for  
69 biennial reviews of pharmacy benefit managers;  
70 authorizing the office to conduct additional  
71 examinations; requiring the office to conduct an  
72 examination under certain circumstances; providing  
73 procedures and requirements for such examinations;  
74 defining the terms "contracts" and "knowing and  
75 willful"; specifying provisions that apply to such  
76 investigations and examinations; providing  
77 recordkeeping requirements for pharmacy benefit  
78 managers; authorizing the office to order the  
79 production of such records and other specified  
80 information; authorizing the office to take statements  
81 under oath; requiring pharmacy benefit managers and  
82 applicants subjected to an investigation or  
83 examination to pay the associated expenses; specifying  
84 covered expenses; providing for collection of such  
85 expenses; providing for the deposit of certain moneys  
86 into the Insurance Regulatory Trust Fund; authorizing  
87 the office to pay examiners, investigators, and other

10-00822D-23

20231550\_\_

88 persons from such fund; providing administrative  
89 penalties; providing grounds for administrative action  
90 against a certificate of authority; amending s.  
91 626.89, F.S.; requiring pharmacy benefit managers to  
92 notify the office of specified complaints,  
93 settlements, or discipline within a specified  
94 timeframe; requiring pharmacy benefit managers to  
95 annually submit a certain attestation statement to the  
96 office; amending s. 627.42393, F.S.; providing that  
97 certain step-therapy protocol requirements apply to a  
98 pharmacy benefit manager acting on behalf of a health  
99 insurer; amending ss. 627.64741 and 627.6572, F.S.;  
100 conforming provisions to changes made by the act;  
101 amending s. 641.31, F.S.; providing that certain step-  
102 therapy protocol requirements apply to a pharmacy  
103 benefit manager acting on behalf of a health  
104 maintenance organization; amending s. 641.314, F.S.;  
105 conforming a provision to changes made by the act;  
106 amending s. 624.491, F.S.; conforming a cross-  
107 reference; providing legislative intent, construction,  
108 and severability; providing an appropriation;  
109 providing an effective date.

110  
111 Be It Enacted by the Legislature of the State of Florida:

112  
113 Section 1. This act may be cited as the "Prescription Drug  
114 Reform Act."

115 Section 2. Subsection (29) is added to section 499.005,  
116 Florida Statutes, to read:

10-00822D-23

20231550\_\_

117 499.005 Prohibited acts.—It is unlawful for a person to  
118 perform or cause the performance of any of the following acts in  
119 this state:

120 (29) Failure to accurately complete and timely submit  
121 reportable drug price increase forms and reports as required  
122 under this part and rules adopted thereunder.

123 Section 3. Subsection (16) is added to section 499.012,  
124 Florida Statutes, to read:

125 499.012 Permit application requirements.—

126 (16) A permit for a prescription drug manufacturer or a  
127 nonresident prescription drug manufacturer is subject to the  
128 requirements of s. 499.026.

129 Section 4. Section 499.026, Florida Statutes, is created to  
130 read:

131 499.026 Notification of manufacturer prescription drug  
132 price increases.—

133 (1) As used in this section, the term:

134 (a) "Course of therapy" means the recommended daily dose  
135 units of a prescription drug pursuant to its prescribing label  
136 for 30 days or the recommended daily dose units of a  
137 prescription drug pursuant to its prescribing label for a normal  
138 course of treatment which is less than 30 days.

139 (b) "Manufacturer" means a person holding a prescription  
140 drug manufacturer permit or a nonresident prescription drug  
141 manufacturer permit under s. 499.01.

142 (c) "Prescription drug" has the same meaning as in s.  
143 499.003 and includes biological products but is limited to those  
144 prescription drugs and biological products intended for human  
145 use.

10-00822D-23

20231550\_\_

146 (d) "Reportable drug price increase" means, for a  
147 prescription drug with a wholesale acquisition cost of at least  
148 \$100 for a course of therapy before the effective date of an  
149 increase:

150 1. Any increase of 15 percent or more of the wholesale  
151 acquisition cost during the preceding 12-month period; or

152 2. Any increase of 40 percent or more of the wholesale  
153 acquisition cost during the preceding 3 calendar years.

154 (e) "Wholesale acquisition cost" means, with respect to a  
155 prescription drug or biological product, the manufacturer's list  
156 price for the prescription drug or biological product to  
157 wholesalers or direct purchasers in the United States, not  
158 including prompt pay or other discounts, rebates, or reductions  
159 in price, for the most recent month for which the information is  
160 available, as reported in wholesale price guides or other  
161 publications of drug or biological product pricing data.

162 (2) On the effective date of a manufacturer's reportable  
163 drug price increase, the manufacturer must provide notification  
164 of each reportable drug price increase to the department on a  
165 form prescribed by the department. The form must require the  
166 manufacturer to specify all of the following:

167 (a) The proprietary and nonproprietary names of the  
168 prescription drug, as applicable.

169 (b) The wholesale acquisition cost before the reportable  
170 drug price increase.

171 (c) The dollar amount of the reportable drug price  
172 increase.

173 (d) The percentage amount of the reportable drug price  
174 increase from the wholesale acquisition cost before the

10-00822D-23

20231550\_\_

175 reportable drug price increase.

176 (e) A statement regarding whether a change or improvement  
177 in the prescription drug necessitates the reportable drug price  
178 increase. If so, the manufacturer must describe the change or  
179 improvement.

180 (f) The intended uses of the prescription drug.

181

182 This subsection does not prohibit a manufacturer from notifying  
183 other parties, such as pharmacy benefit managers, of a drug  
184 price increase before the effective date of the drug price  
185 increase.

186 (3) By April 1 of each year, each manufacturer shall submit  
187 a report to the department on a form prescribed by the  
188 department. A report is not deemed to be submitted until  
189 approved by the department. At a minimum, the report must  
190 include all of the following:

191 (a) A list of all prescription drugs affected by a  
192 reportable drug price increase during the previous calendar year  
193 and both the dollar amount of each reportable drug price  
194 increase and the percentage increase of each reportable drug  
195 price increase relative to the previous wholesale acquisition  
196 cost of the prescription drug. The prescription drugs shall be  
197 identified using their proprietary names and nonproprietary  
198 names, as applicable.

199 (b) If more than one form has been filed under this section  
200 for previous reportable drug price increases, the percentage  
201 increase of the prescription drug from the earliest form filed  
202 to the most recent form filed.

203 (c) The intended uses of each prescription drug listed in

10-00822D-23

20231550\_\_

204 the report and whether the prescription drug manufacturer  
205 benefits from market exclusivity for such drug.

206 (d) The length of time the prescription drug has been  
207 available for purchase.

208 (e) A complete description of the factors contributing to  
209 each reportable drug price increase. The factors must be  
210 provided with such specificity as to explain the need or  
211 justification for each reportable drug price increase. The  
212 department may request additional information from a  
213 manufacturer relating to the need or justification of any  
214 reportable drug price increase before approving the  
215 manufacturer's report.

216 (f) Any action that the manufacturer has filed to extend a  
217 patent report after the first extension has been granted.

218 (4) (a) The department shall submit all forms and reports  
219 submitted by manufacturers to the Agency for Health Care  
220 Administration, to be posted on the agency's website pursuant to  
221 s. 408.062.

222 (b) A manufacturer may not claim a public records exemption  
223 for a trade secret under s. 119.0715 for any information  
224 required by the department under this section. Department  
225 employees remain protected from liability for release of forms  
226 and reports pursuant to s. 119.0715(4).

227 (5) The department, in consultation with the Agency for  
228 Health Care Administration, shall adopt rules to implement this  
229 section.

230 (a) The department shall adopt necessary emergency rules  
231 pursuant to s. 120.54(4) to implement this section. If an  
232 emergency rule adopted under this section is held to be



10-00822D-23

20231550\_\_

233 unconstitutional or an invalid exercise of delegated legislative  
234 authority and becomes void, the department may adopt an  
235 emergency rule pursuant to this section to replace the rule that  
236 has become void. If the emergency rule adopted to replace the  
237 void emergency rule is also held to be unconstitutional or an  
238 invalid exercise of delegated legislative authority and becomes  
239 void, the department shall follow the nonemergency rulemaking  
240 procedures of the Administrative Procedure Act to replace the  
241 rule that has become void.

242 (b) For emergency rules adopted under this section, the  
243 department need not make the findings required under s.  
244 120.54(4)(a). Emergency rules adopted under this section are  
245 also exempt from:

246 1. Sections 120.54(3)(b) and 120.541. Challenges to  
247 emergency rules adopted under this section are subject to the  
248 time schedules provided in s. 120.56(5).

249 2. Section 120.54(4)(c), and remain in effect until  
250 replaced by rules adopted under the nonemergency rulemaking  
251 procedures of the Administrative Procedure Act.

252 Section 5. Paragraph (a) of subsection (10) of section  
253 624.307, Florida Statutes, is amended, and paragraph (b) of that  
254 subsection is republished, to read:

255 624.307 General powers; duties.—

256 (10) (a) The Division of Consumer Services shall perform the  
257 following functions concerning products or services regulated by  
258 the department or office:

259 1. Receive inquiries and complaints from consumers.

260 2. Prepare and disseminate information that the department  
261 deems appropriate to inform or assist consumers.

10-00822D-23

20231550\_\_

262 3. Provide direct assistance to and advocacy for consumers  
263 who request such assistance or advocacy.

264 4. With respect to apparent or potential violations of law  
265 or applicable rules committed by a person or entity licensed by  
266 the department or office, report apparent or potential  
267 violations to the office or to the appropriate division of the  
268 department, which may take any additional action it deems  
269 appropriate.

270 5. Designate an employee of the division as the primary  
271 contact for consumers on issues relating to sinkholes.

272 6. Designate an employee of the division as the primary  
273 contact for consumers on issues relating to pharmacy benefit  
274 managers. The division must refer to the office any consumer  
275 complaint that alleges conduct that may constitute a violation  
276 of part VII of chapter 626 or for which a pharmacy benefit  
277 manager does not respond in accordance with paragraph (b).

278 (b) Any person licensed or issued a certificate of  
279 authority by the department or the office shall respond, in  
280 writing, to the division within 20 days after receipt of a  
281 written request for documents and information from the division  
282 concerning a consumer complaint. The response must address the  
283 issues and allegations raised in the complaint and include any  
284 requested documents concerning the consumer complaint not  
285 subject to attorney-client or work-product privilege. The  
286 division may impose an administrative penalty for failure to  
287 comply with this paragraph of up to \$2,500 per violation upon  
288 any entity licensed by the department or the office and \$250 for  
289 the first violation, \$500 for the second violation, and up to  
290 \$1,000 for the third or subsequent violation upon any individual

10-00822D-23

20231550\_\_

291 licensed by the department or the office.

292 Section 6. Subsection (1) of section 624.490, Florida  
293 Statutes, is amended to read:

294 624.490 Registration of pharmacy benefit managers.—

295 (1) As used in this section, the term "pharmacy benefit  
296 manager" has the same meaning as in s. 626.88 ~~means a person or~~  
297 ~~entity doing business in this state which contracts to~~  
298 ~~administer prescription drug benefits on behalf of a health~~  
299 ~~insurer or a health maintenance organization to residents of~~  
300 ~~this state.~~

301 Section 7. Subsection (1) of section 626.88, Florida  
302 Statutes, is amended, and subsection (6) is added to that  
303 section, to read:

304 626.88 Definitions.—For the purposes of this part, the  
305 term:

306 (1) "Administrator" means ~~is~~ any person who directly or  
307 indirectly solicits or effects coverage of, collects charges or  
308 premiums from, or adjusts or settles claims on residents of this  
309 state in connection with authorized commercial self-insurance  
310 funds or with insured or self-insured programs which provide  
311 life or health insurance coverage or coverage of any other  
312 expenses described in s. 624.33(1); ~~or~~ any person who, through a  
313 health care risk contract as defined in s. 641.234 with an  
314 insurer or health maintenance organization, provides billing and  
315 collection services to health insurers and health maintenance  
316 organizations on behalf of health care providers; or a pharmacy  
317 benefit manager. The term does not include, ~~other than~~ any of  
318 the following ~~persons~~:

319 (a) An employer or wholly owned direct or indirect

10-00822D-23

20231550\_\_

320 subsidiary of an employer, on behalf of such employer's  
321 employees or the employees of one or more subsidiary or  
322 affiliated corporations of such employer.

323 (b) A union on behalf of its members.

324 (c) An insurance company which is either authorized to  
325 transact insurance in this state or is acting as an insurer with  
326 respect to a policy lawfully issued and delivered by such  
327 company in and pursuant to the laws of a state in which the  
328 insurer was authorized to transact an insurance business.

329 (d) A health care services plan, health maintenance  
330 organization, professional service plan corporation, or person  
331 in the business of providing continuing care, possessing a valid  
332 certificate of authority issued by the office, and the sales  
333 representatives thereof, if the activities of such entity are  
334 limited to the activities permitted under the certificate of  
335 authority.

336 (e) An entity that is affiliated with an insurer and that  
337 only performs the contractual duties, between the administrator  
338 and the insurer, of an administrator for the direct and assumed  
339 insurance business of the affiliated insurer. The insurer is  
340 responsible for the acts of the administrator and is responsible  
341 for providing all of the administrator's books and records to  
342 the insurance commissioner, upon a request from the insurance  
343 commissioner. For purposes of this paragraph, the term "insurer"  
344 means a licensed insurance company, health maintenance  
345 organization, prepaid limited health service organization, or  
346 prepaid health clinic.

347 (f) A nonresident entity licensed in its state of domicile  
348 as an administrator if its duties in this state are limited to

10-00822D-23

20231550\_\_

349 the administration of a group policy or plan of insurance and no  
350 more than a total of 100 lives for all plans reside in this  
351 state.

352 (g) An insurance agent licensed in this state whose  
353 activities are limited exclusively to the sale of insurance.

354 (h) A person appointed as a managing general agent in this  
355 state, whose activities are limited exclusively to the scope of  
356 activities conveyed under such appointment.

357 (i) An adjuster licensed in this state whose activities are  
358 limited to the adjustment of claims.

359 (j) A creditor on behalf of such creditor's debtors with  
360 respect to insurance covering a debt between the creditor and  
361 its debtors.

362 (k) A trust and its trustees, agents, and employees acting  
363 pursuant to such trust established in conformity with 29 U.S.C.  
364 s. 186.

365 (l) A trust exempt from taxation under s. 501(a) of the  
366 Internal Revenue Code, a trust satisfying the requirements of  
367 ss. 624.438 and 624.439, or any governmental trust as defined in  
368 s. 624.33(3), and the trustees and employees acting pursuant to  
369 such trust, or a custodian and its agents and employees,  
370 including individuals representing the trustees in overseeing  
371 the activities of a service company or administrator, acting  
372 pursuant to a custodial account which meets the requirements of  
373 s. 401(f) of the Internal Revenue Code.

374 (m) A financial institution which is subject to supervision  
375 or examination by federal or state authorities or a mortgage  
376 lender licensed under chapter 494 who collects and remits  
377 premiums to licensed insurance agents or authorized insurers

10-00822D-23

20231550\_\_

378 concurrently or in connection with mortgage loan payments.

379 (n) A credit card issuing company which advances for and  
380 collects premiums or charges from its credit card holders who  
381 have authorized such collection if such company does not adjust  
382 or settle claims.

383 (o) A person who adjusts or settles claims in the normal  
384 course of such person's practice or employment as an attorney at  
385 law and who does not collect charges or premiums in connection  
386 with life or health insurance coverage.

387 (p) A person approved by the department who administers  
388 only self-insured workers' compensation plans.

389 (q) A service company or service agent and its employees,  
390 authorized in accordance with ss. 626.895-626.899, serving only  
391 a single employer plan, multiple-employer welfare arrangements,  
392 or a combination thereof.

393 (r) Any provider or group practice, as defined in s.  
394 456.053, providing services under the scope of the license of  
395 the provider or the member of the group practice.

396 (s) Any hospital providing billing, claims, and collection  
397 services solely on its own and its physicians' behalf and  
398 providing services under the scope of its license.

399 (t) A corporation not for profit whose membership consists  
400 entirely of local governmental units authorized to enter into  
401 risk management consortiums under s. 112.08.

402

403 A person who provides billing and collection services to health  
404 insurers and health maintenance organizations on behalf of  
405 health care providers shall comply with the provisions of ss.  
406 627.6131, 641.3155, and 641.51(4).

10-00822D-23

20231550\_\_

407       (6) "Pharmacy benefit manager" means a person or entity  
408 doing business in this state which contracts to administer  
409 prescription drug benefits on behalf of a pharmacy benefits plan  
410 or program as defined in s. 626.8825. The term includes, but is  
411 not limited to, a person or entity that performs one or more of  
412 the following services:

413       (a) Pharmacy claims processing.

414       (b) Administration or management of pharmacy discount card  
415 programs.

416       (c) Managing pharmacy networks or pharmacy reimbursement.

417       (d) Paying or managing claims for pharmacist services  
418 provided to covered persons.

419       (e) Developing or managing a clinical formulary, including  
420 utilization management or quality assurance programs.

421       (f) Pharmacy rebate administration.

422       (g) Managing patient compliance, therapeutic intervention,  
423 or generic substitution programs.

424       Section 8. Present subsections (3) through (6) of section  
425 626.8805, Florida Statutes, are redesignated as subsection (4)  
426 through (7), respectively, a new subsection (3) and subsection  
427 (8) are added to that section, and subsection (1) and present  
428 subsection (3) of that section are amended, to read:

429       626.8805 Certificate of authority to act as administrator.—

430       (1) It is unlawful for any person to act as or hold himself  
431 or herself out to be an administrator in this state without a  
432 valid certificate of authority issued by the office pursuant to  
433 ss. 626.88-626.894. A pharmacy benefit manager that is  
434 registered with the office under s. 624.490 as of June 30, 2023,  
435 may continue to operate until January 1, 2024, as an

10-00822D-23

20231550\_\_

436 administrator without a certificate of authority and is not in  
437 violation of the requirement to possess a valid certificate of  
438 authority as an administrator during that timeframe. To qualify  
439 for and hold authority to act as an administrator in this state,  
440 an administrator must otherwise be in compliance with this code  
441 and with its organizational agreement. The failure of any  
442 person, excluding a pharmacy benefit manager, to hold such a  
443 certificate while acting as an administrator shall subject such  
444 person to a fine of not less than \$5,000 or more than \$10,000  
445 for each violation. A person who, on or after January 1, 2024,  
446 does not hold a certificate of authority to act as an  
447 administrator while operating as a pharmacy benefit manager is  
448 subject to a fine of \$10,000 per violation per day.

449 (3) An applicant that is a pharmacy benefit manager must  
450 also submit all of the following:

451 (a) A complete biographical statement on forms prescribed  
452 by the commission, an independent investigation report, and  
453 fingerprints obtained pursuant to chapter 624, of all of the  
454 individuals referred to in paragraph (2) (c).

455 (b) A self-disclosure of any administrative, civil, or  
456 criminal complaints, settlements, or discipline of the  
457 applicant, or any of the applicant's affiliates, which relate to  
458 a violation of the insurance laws, including pharmacy benefit  
459 manager laws, in any state.

460 (c) A statement attesting to compliance with the network  
461 requirements in s. 626.8825 beginning January 1, 2024.

462 (4) (a) The applicant shall make available for inspection by  
463 the office copies of all contracts relating to services provided  
464 by the administrator to insurers or other persons using the



10-00822D-23

20231550\_\_

465 services of the administrator.

466 (b) An applicant that is a pharmacy benefit manager shall  
467 also make available for inspection by the office:

468 1. Copies of all contract templates with any pharmacy as  
469 defined in s. 465.003; and

470 2. Copies of all subcontracts to support its operations.

471 (8) A pharmacy benefit manager is exempt from fees  
472 associated with the initial application and the annual filing  
473 fees in s. 626.89.

474 Section 9. Section 626.8814, Florida Statutes, is amended  
475 to read:

476 626.8814 Disclosure of ownership or affiliation.—

477 (1) Each administrator shall identify to the office any  
478 ownership interest or affiliation of any kind with any insurance  
479 company responsible for providing benefits directly or through  
480 reinsurance to any plan for which the administrator provides  
481 administrative services.

482 (2) Pharmacy benefit managers shall also identify to the  
483 office any ownership affiliation of any kind with any pharmacy  
484 which, either directly or indirectly, through one or more  
485 intermediaries:

486 (a) Has an investment or ownership interest in a pharmacy  
487 benefit manager holding a certificate of authority issued under  
488 this part;

489 (b) Shares common ownership with a pharmacy benefit manager  
490 holding a certificate of authority issued under this part; or

491 (c) Has an investor or a holder of an ownership interest  
492 which is a pharmacy benefit manager holding a certificate of  
493 authority issued under this part.

10-00822D-23

20231550\_\_

494 (3) A pharmacy benefit manager shall report any change in  
495 information required by subsection (2) to the office in writing  
496 within 60 days after the change occurs.

497 Section 10. Section 626.8825, Florida Statutes, is created  
498 to read:

499 626.8825 Pharmacy benefit manager transparency and  
500 accountability.-

501 (1) DEFINITIONS.-As used in this section, the term:

502 (a) "Adjudication transaction fee" means a fee charged by  
503 the pharmacy benefit manager to the pharmacy for electronic  
504 claim submissions.

505 (b) "Affiliated pharmacy" means a pharmacy that, either  
506 directly or indirectly through one or more intermediaries:

507 1. Has an investment or ownership interest in a pharmacy  
508 benefit manager holding a certificate of authority issued under  
509 this part;

510 2. Shares common ownership with a pharmacy benefit manager  
511 holding a certificate of authority issued under this part; or

512 3. Has an investor or a holder of an ownership interest  
513 which is a pharmacy benefit manager holding a certificate of  
514 authority issued under this part.

515 (c) "Brand name or generic effective rate" means the  
516 contractual rate set forth by a pharmacy benefit manager for the  
517 reimbursement of covered brand name or generic drugs, calculated  
518 using the total payments in the aggregate, by drug type, during  
519 the performance period. The effective rates are typically  
520 calculated as a discount from industry benchmarks, such as  
521 average wholesale price or wholesale acquisition cost.

522 (d) "Covered person" means a person covered by,

10-00822D-23

20231550\_\_

523 participating in, or receiving the benefit of a pharmacy  
524 benefits plan or program.

525 (e) "Direct and indirect remuneration fees" means price  
526 concessions that are paid to the pharmacy benefit manager by the  
527 pharmacy retrospectively and that cannot be calculated at the  
528 point of sale. The term may also include discounts, chargebacks  
529 or rebates, cash discounts, free goods contingent on a purchase  
530 agreement, upfront payments, coupons, goods in kind, free or  
531 reduced-price services, grants, or other price concessions or  
532 similar benefits from manufacturers, pharmacies, or similar  
533 entities.

534 (f) "Dispensing fee" means a fee intended to cover  
535 reasonable costs associated with providing the drug to a covered  
536 person. This cost includes the pharmacist's services and the  
537 overhead associated with maintaining the facility and equipment  
538 necessary to operate the pharmacy.

539 (g) "Effective rate guarantee" means the minimum ingredient  
540 cost reimbursement a pharmacy benefit manager guarantees it will  
541 pay for pharmacist services during the applicable measurement  
542 period.

543 (h) "Erroneous claims" means pharmacy claims submitted in  
544 error, including, but not limited to, unintended, incorrect,  
545 fraudulent, or test claims.

546 (i) "Incentive payment" means a retrospective monetary  
547 payment made as a reward or recognition by the pharmacy benefits  
548 plan or program or pharmacy benefit manager to a pharmacy for  
549 meeting or exceeding predefined pharmacy performance metrics as  
550 related to quality measure, such as Healthcare Effectiveness  
551 Data and Information Set measures.

10-00822D-23

20231550\_\_

552       (j) "Maximum allowable cost appeal pricing adjustment"  
553 means a retrospective positive payment adjustment made to a  
554 pharmacy by the pharmacy benefits plan or program or by the  
555 pharmacy benefit manager pursuant to an approved maximum  
556 allowable cost appeal request submitted by the same pharmacy to  
557 dispute the amount reimbursed for a drug based on the pharmacy  
558 benefit manager's listed maximum allowable cost price.

559       (k) "Monetary recoupments" means rescinded or recouped  
560 payments from a pharmacy or provider by the pharmacy benefits  
561 plan or program or by the pharmacy benefit manager.

562       (l) "Network" means a pharmacy or group of pharmacies that  
563 agree to provide pharmacist services to covered persons on  
564 behalf of a pharmacy benefits plan or program or a group of  
565 pharmacy benefits plans or programs in exchange for payment for  
566 such services. The term includes a pharmacy that generally  
567 dispenses outpatient prescription drugs to covered persons or  
568 dispenses particular types of prescription drugs, provides  
569 pharmacist services to particular types of covered persons, or  
570 dispenses prescriptions in particular health care settings,  
571 including networks of specialty, institutional, or long-term  
572 care facilities.

573       (m) "Network reconciliation offsets" means a process during  
574 annual payment reconciliation between a pharmacy benefit manager  
575 and a pharmacy which allows the pharmacy benefit manager to  
576 offset an amount for overperformance or underperformance of  
577 contractual guarantees across guaranteed line items, channels,  
578 networks, or payers, as applicable.

579       (n) "Participation contract" means any agreement between a  
580 pharmacy benefit manager and pharmacy for the provision and

10-00822D-23

20231550\_\_

581 reimbursement of pharmacist services and any exhibits,  
582 attachments, amendments, or addendums to such agreement.

583 (o) "Pass-through pricing model" means a payment model used  
584 by a pharmacy benefit manager in which the payments made by the  
585 pharmacy benefits plan or program to the pharmacy benefit  
586 manager for the covered outpatient drugs are:

587 1. Equivalent to the payments the pharmacy benefit manager  
588 makes to a dispensing pharmacy or provider for such drugs,  
589 including any contracted professional dispensing fee between the  
590 pharmacy benefit manager and its network of pharmacies. Such  
591 dispensing fee would be paid if the pharmacy benefits plan or  
592 program was making the payments directly.

593 2. Passed through in their entirety by the pharmacy  
594 benefits plan or program or by the pharmacy benefit manager to  
595 the pharmacy or provider that dispenses the drugs, and the  
596 payments are made in a manner that is not offset by any  
597 reconciliation.

598 (p) "Pharmacist" means a pharmacist as defined in s.  
599 465.003.

600 (q) "Pharmacist services" means products, goods, and  
601 services or any combination of products, goods, and services  
602 provided as part of the practice of the profession of pharmacy  
603 as defined in s. 465.003 or otherwise covered by a pharmacy  
604 benefits plan or program.

605 (r) "Pharmacy" means a pharmacy as defined in s. 465.003.

606 (s) "Pharmacy benefit manager" has the same meaning as in  
607 s. 626.88.

608 (t) "Pharmacy benefits plan or program" means a plan or  
609 program that pays for, reimburses, covers the cost of, or

10-00822D-23

20231550\_\_

610 provides access to discounts on pharmacist services provided by  
611 one or more pharmacies to covered persons who reside in, are  
612 employed by, or receive pharmacist services from this state. The  
613 term includes, but is not limited to, health maintenance  
614 organizations, health insurers, self-insured employer health  
615 plans, discount card programs, and government-funded health  
616 plans, including the Statewide Medicaid Managed Care program  
617 established pursuant to part IV of chapter 409 and the state  
618 group insurance program pursuant to part I of chapter 110.

619 (u) "Rebate" means all payments that accrue to a pharmacy  
620 benefit manager or its pharmacy benefits plan or program client,  
621 directly or indirectly, from a pharmaceutical manufacturer,  
622 including, but not limited to, discounts, administration fees,  
623 credits, incentives, or penalties associated directly or  
624 indirectly in any way with claims administered on behalf of a  
625 pharmacy benefits plan or program client.

626 (v) "Spread pricing" is the practice in which a pharmacy  
627 benefit manager charges a pharmacy benefits plan or program a  
628 different amount for pharmacist services than the amount the  
629 pharmacy benefit manager reimburses a pharmacy for such  
630 pharmacist services.

631 (w) "Usual and customary price" means the amount charged to  
632 cash customers for a pharmacist service exclusive of sales tax  
633 or other amounts claimed.

634 (2) CONTRACTS BETWEEN A PHARMACY BENEFIT MANAGER AND A  
635 PHARMACY BENEFITS PLAN OR PROGRAM.—In addition to any other  
636 requirements in the Florida Insurance Code, all contractual  
637 arrangements executed, amended, adjusted, or renewed on or after  
638 July 1, 2023, which are applicable to pharmacy benefits covered

10-00822D-23

20231550\_\_

639 on or after January 1, 2024, between a pharmacy benefit manager  
640 and a pharmacy benefits plan or program must:

641 (a) Use a pass-through pricing model, remaining consistent  
642 with the prohibition in paragraph (3) (c).

643 (b) Exclude terms that allow for the direct or indirect  
644 engagement in the practice of spread pricing unless the pharmacy  
645 benefit manager passes along the entire amount of such  
646 difference to the pharmacy benefits plan or program as allowable  
647 under paragraph (a).

648 (c) Ensure that funds received in relation to providing  
649 services for a pharmacy benefits plan or program or a pharmacy  
650 are received by the pharmacy benefit manager in trust for the  
651 pharmacy benefits plan or program or pharmacy, as applicable,  
652 and are used or distributed only pursuant to the pharmacy  
653 benefit manager's contract with the pharmacy benefits plan or  
654 program or with the pharmacy or as otherwise required by  
655 applicable law.

656 (d) Include network adequacy requirements that meet or  
657 exceed the Medicare Part D program standards for convenient  
658 access to network pharmacies set forth in 42 C.F.R. s. 423.120,  
659 and that:

660 1. Do not limit a network to solely include affiliated  
661 pharmacies;

662 2. Require a pharmacy benefit manager to offer a provider  
663 contract to licensed pharmacies physically located on the  
664 physical site of providers within the pharmacy benefits plan's  
665 or program's geographic service area which have been  
666 specifically designated as essential providers by the Agency for  
667 Health Care Administration pursuant to s. 409.975(1) (a), and

10-00822D-23

20231550\_\_

668 Florida cancer hospitals that meet the criteria in s.  
669 409.975(1)(b), regardless of the pharmacy benefits plan's or  
670 program's geographic service area, solely for the administration  
671 or dispensing of covered prescription drugs, including  
672 biological products, that are administered through infusions,  
673 intravenously injected, inhaled during a surgical procedure, or  
674 a covered parenteral drug, as part of onsite outpatient care;

675 3. Do not require a covered person to receive a  
676 prescription drug by United States mail, common carrier, local  
677 courier, third-party company or delivery service, or pharmacy  
678 direct delivery. This subparagraph does not prohibit a pharmacy  
679 benefit manager from operating mail order or delivery programs  
680 on an opt-in basis at the sole discretion of a covered person;

681 4. Prohibit a requirement for a covered person to receive  
682 pharmacist services from an affiliated pharmacy or an affiliated  
683 health care provider for the in-person administration of covered  
684 prescription drugs; offering or implementing pharmacy networks  
685 that require or incentivize a covered person to use an  
686 affiliated pharmacy or an affiliated health care provider for  
687 the in-person administration of covered prescription drugs; or  
688 advertising, marketing, or promoting an affiliated pharmacy to  
689 covered persons. Subject to the foregoing, a pharmacy benefit  
690 manager may include an affiliated pharmacy in communications to  
691 covered persons regarding network pharmacies and prices,  
692 provided that the pharmacy benefit manager includes information,  
693 such as links to all nonaffiliated network pharmacies, in such  
694 communications and that the information provided is accurate and  
695 of equal prominence. This paragraph may not be construed to  
696 prohibit a pharmacy benefit manager from entering into an



10-00822D-23

20231550\_\_

697 agreement with an affiliated pharmacy to provide pharmacist  
698 services to covered persons.

699 (e) Prohibit the ability of a pharmacy benefit manager to  
700 condition participation in one pharmacy network on participation  
701 in any other pharmacy network or penalize a pharmacy for  
702 exercising its prerogative not to participate in a specific  
703 pharmacy network.

704 (f) Prohibit a pharmacy benefit manager from instituting a  
705 network that requires a pharmacy to meet accreditation standards  
706 inconsistent with or more stringent than applicable federal and  
707 state requirements for licensure and operation as a pharmacy in  
708 this state.

709 (3) CONTRACTS BETWEEN A PHARMACY BENEFIT MANAGER AND A  
710 PARTICIPATING PHARMACY.—In addition to other requirements in the  
711 Florida Insurance Code, a participation contract executed,  
712 amended, adjusted, or renewed on or after July 1, 2023, that  
713 applies to pharmacist services on or after January 1, 2024,  
714 between a pharmacy benefit manager and one or more pharmacies or  
715 pharmacists, must include, in substantial form, terms that  
716 ensure compliance with all of the following requirements, and  
717 which, except to the extent not allowed by law, shall supersede  
718 any contractual terms in the participation contract to the  
719 contrary:

720 (a) At the time of adjudication for electronic claims or  
721 the time of reimbursement for non-electronic claims, the  
722 pharmacy benefit manager shall provide the pharmacy with a  
723 remittance, including such detailed information as is necessary  
724 for the pharmacy or pharmacist to identify the reimbursement  
725 schedule for the specific network applicable to the claim and

10-00822D-23

20231550\_\_

726 which is the basis used by the pharmacy benefit manager to  
727 calculate the amount of reimbursement paid. This information  
728 must include, but is not limited to, the applicable network  
729 reimbursement ID or plan ID as defined in the most current  
730 version of the National Council for Prescription Drug Programs  
731 (NCPDP) Telecommunication Standard Implementation Guide, or its  
732 nationally recognized successor industry guide. The office shall  
733 adopt rules to implement this paragraph.

734 (b) The pharmacy benefit manager must ensure that any basis  
735 of reimbursement information is communicated to a pharmacy in  
736 accordance with the NCPDP Telecommunication Standard  
737 Implementation Guide, or its nationally recognized successor  
738 industry guide, when performing reconciliation for any effective  
739 rate guarantee, and that such basis of reimbursement information  
740 communicated is accurate, corresponds with the applicable  
741 network rate, and may be relied upon by the pharmacy.

742 (c) A prohibition of financial clawbacks or reconciliation  
743 offsets. A pharmacy benefit manager may not recoup direct or  
744 indirect remuneration fees, dispensing fees, brand name or  
745 generic effective rate adjustments through reconciliation, or  
746 any other monetary recoupments as related to discounts, multiple  
747 network reconciliation offsets, adjudication transaction fees,  
748 and any other instance when a fee may be recouped from a  
749 pharmacy. For purposes of this section, the terms "financial  
750 clawbacks" or "reconciliation offsets" do not include:

751 1. Any incentive payments provided by the pharmacy benefit  
752 manager to a network pharmacy for meeting or exceeding  
753 predefined quality measures, such as Healthcare Effectiveness  
754 Data and Information Set measures; recoupment due to an

10-00822D-23

20231550\_\_

755 erroneous claim, fraud, waste, or abuse; a claim adjudicated in  
756 error; a maximum allowable cost appeal pricing adjustment; or an  
757 adjustment made as part of a pharmacy audit pursuant to s.  
758 624.491.

759 2. Any recoupment that is returned to the state for  
760 programs in chapter 409 or the state group insurance program in  
761 s. 110.123.

762 (d) A pharmacy benefit manager may not unilaterally change  
763 the terms of any participation contract.

764 (e) The pharmacy benefit manager must provide a pharmacy,  
765 upon its request, a list of pharmacy benefits plans or programs  
766 in which the pharmacy is a part of the network. Updates to the  
767 list must be communicated to the pharmacy within 7 days. The  
768 pharmacy benefit manager may not restrict the pharmacy or  
769 pharmacist from disclosing this information to the public.

770 (f) The pharmacy benefit manager must ensure that the  
771 Electronic Remittance Advice contains claim level payment  
772 adjustments in accordance with American National Standards  
773 Institute Accredited Standard Committee, X12 format, and must  
774 include or be accompanied by the appropriate level of detail for  
775 the pharmacy to reconcile any debits or credits, including, but  
776 not limited to, pharmacy NCPDP or NPI identifier, date of  
777 service, prescription number, refill number, adjustment code, if  
778 applicable, and transaction amount.

779 (g) The pharmacy benefit manager shall provide a reasonable  
780 administrative appeal procedure to allow a pharmacy or  
781 pharmacist to challenge the maximum allowable cost pricing  
782 information and the reimbursement made under the maximum  
783 allowable cost for a specific drug as being below the

10-00822D-23

20231550\_\_

784 acquisition cost available to the challenging pharmacy or  
785 pharmacist.

786 1. The administrative appeal procedure must include a  
787 telephone number and e-mail address, or a website, for the  
788 purpose of submitting the administrative appeal. The appeal may  
789 be submitted directly to the pharmacy benefit manager or through  
790 a pharmacy service administration organization. The pharmacy or  
791 pharmacist must be given at least 30 business days after a  
792 maximum allowable cost update or after an adjudication for an  
793 electronic claim or reimbursement for a non-electronic claim to  
794 file the administrative appeal.

795 2. The pharmacy benefit manager must respond to the  
796 administrative appeal within 30 business days after receipt of  
797 the appeal.

798 3. If the appeal is upheld, the pharmacy benefit manager  
799 must:

800 a. Update the maximum allowable cost pricing information to  
801 at least the acquisition cost available to the pharmacy;

802 b. Permit the pharmacy or pharmacist to reverse and rebill  
803 the claim in question;

804 c. Provide to the pharmacy or pharmacist the national drug  
805 code on which the increase or change is based; and

806 d. Make the increase or change effective for each similarly  
807 situated pharmacy or pharmacist who is subject to the applicable  
808 maximum allowable cost pricing information.

809 4. If the appeal is denied, the pharmacy benefit manager  
810 must provide to the pharmacy or pharmacist the national drug  
811 code and the name of the national or regional pharmaceutical  
812 wholesalers operating in this state which have the drug

10-00822D-23

20231550\_\_

813 currently in stock at a price below the maximum allowable cost  
814 pricing information.

815 5. If the drug with the national drug code provided by the  
816 pharmacy benefit manager is not available below the acquisition  
817 cost to the pharmacy or pharmacist from the pharmaceutical  
818 wholesaler from whom the pharmacy or pharmacist purchases the  
819 majority of drugs for resale, the pharmacy benefits manager must  
820 adjust the maximum allowable cost pricing information above the  
821 acquisition cost to the pharmacy or pharmacist and permit the  
822 pharmacy or pharmacist to reverse and rebill each claim affected  
823 by the pharmacy's or pharmacist's inability to procure the drug  
824 at a cost that is equal to or less than the previously  
825 challenged maximum allowable cost.

826 6. Every 90 days, a pharmacy benefit manager shall report  
827 to the office the total number of appeals received and denied in  
828 the preceding 90-day period for each specific drug for which an  
829 appeal was submitted pursuant to this paragraph.

830 Section 11. Section 626.8827, Florida Statutes, is created  
831 to read:

832 626.8827 Pharmacy benefit manager prohibited practices.—In  
833 addition to other prohibitions in this part, a pharmacy benefit  
834 manager may not do any of the following:

835 (1) Prohibit, restrict, or penalize in any way a pharmacy  
836 or pharmacist from disclosing to any person any information that  
837 the pharmacy or pharmacist deems appropriate, including, but not  
838 limited to, information regarding any of the following:

839 (a) The nature of treatment, risks, or alternatives  
840 thereto.

841 (b) The availability of alternate treatment, consultations,

10-00822D-23

20231550\_\_

842 or tests.

843 (c) The decision of utilization reviewers or similar  
844 persons to authorize or deny pharmacist services.

845 (d) The process used to authorize or deny pharmacist  
846 services or benefits.

847 (e) Information on financial incentives and structures used  
848 by the pharmacy benefits plan or program.

849 (f) Information that may reduce the costs of pharmacist  
850 services.

851 (g) Whether the cost-sharing obligation exceeds the retail  
852 price for a covered prescription drug and the availability of a  
853 more affordable alternative drug, pursuant to s. 465.0244.

854 (2) Prohibit, restrict, or penalize in any way a pharmacy  
855 or pharmacist from disclosing information to the office, the  
856 Agency for Health Care Administration, Department of Management  
857 Services, law enforcement, or state and federal governmental  
858 officials, provided that the recipient of the information  
859 represents it has the authority, to the extent provided by state  
860 or federal law, to maintain proprietary information as  
861 confidential; and before disclosure of information designated as  
862 confidential, the pharmacist or pharmacy marks as confidential  
863 any document in which the information appears or requests  
864 confidential treatment for any oral communication of the  
865 information.

866 (3) Communicate at the point-of-sale, or otherwise require,  
867 a cost-sharing obligation for the covered person in an amount  
868 that exceeds the lesser of:

869 (a) The applicable cost-sharing amount under the applicable  
870 pharmacy benefits plan or program; or

10-00822D-23

20231550\_\_

871 (b) The usual and customary price, as defined in s.  
872 626.8825, of the pharmacist services.

873 (4) Transfer or share records relative to prescription  
874 information containing patient-identifiable or prescriber-  
875 identifiable data to an affiliated pharmacy for any commercial  
876 purpose other than the limited purposes of facilitating pharmacy  
877 reimbursement, formulary compliance, or utilization review on  
878 behalf of the applicable pharmacy benefits plan or program.

879 (5) Fail to make any payment due to a pharmacy for an  
880 adjudicated claim with a date of service before the effective  
881 date of a pharmacy's termination from a pharmacy benefit network  
882 unless payments are withheld because of actual fraud on the part  
883 of the pharmacy or except as otherwise required by law.

884 (6) Terminate the contract of, penalize, or disadvantage a  
885 pharmacist or pharmacy due to a pharmacist or pharmacy:

886 (a) Disclosing information about pharmacy benefit manager  
887 practices in accordance with this act;

888 (b) Exercising any of its prerogatives under this part; or

889 (c) Sharing any portion, or all, of the pharmacy benefit  
890 manager contract with the office pursuant to a complaint or a  
891 query regarding whether the contract is in compliance with this  
892 act.

893 (7) Fail to comply with the requirements in s. 626.8825.

894 Section 12. Section 626.8828, Florida Statutes, is created  
895 to read:

896 626.8828 Investigations and examinations of pharmacy  
897 benefit managers; expenses; penalties.—

898 (1) The office may investigate administrators who are  
899 pharmacy benefit managers and applicants for authorization as

10-00822D-23

20231550\_\_

900 provided in ss. 624.307 and 624.317. The office must review any  
901 referral made pursuant to s. 624.307(10) and must investigate  
902 any referral that, as determined by the Commissioner of  
903 Insurance Regulation or his or her designee, reasonably  
904 indicates a possible violation of this part.

905 (2) (a) The office shall examine the business and affairs of  
906 each pharmacy benefit manager at least biennially. The biennial  
907 examination of each pharmacy benefit manager must be a  
908 systematic review for the purpose of determining the pharmacy  
909 benefit manager's compliance with all provisions of this part  
910 and all other laws or rules applicable to pharmacy benefit  
911 managers and must include a detailed review of the pharmacy  
912 benefit manager's compliance with ss. 626.8825 and 626.8827. The  
913 first 2-year cycle for conducting biennial reviews begins July  
914 1, 2023. By January 1 of the year following a 2-year cycle, the  
915 office must deliver to the Governor, the President of the  
916 Senate, and the Speaker of the House of Representatives a report  
917 summarizing the results of the biennial examinations during the  
918 most recent 2-year cycle which includes detailed descriptions of  
919 any violations committed by each pharmacy benefit manager and  
920 detailed reporting of actions taken by the office against each  
921 pharmacy benefit manager for such violations.

922 (b) The office also may conduct additional examinations as  
923 often as it deems advisable or necessary for the purpose of  
924 ascertaining compliance with this part and any other laws or  
925 rules applicable to pharmacy benefit managers or applicants for  
926 authorization.

927 (c) If a referral made pursuant to s. 624.307(10)  
928 reasonably indicates a pattern or practice of violations of this



10-00822D-23

20231550\_\_

929 part by a pharmacy benefit manager, the office must begin an  
930 examination of the pharmacy benefit manager or include findings  
931 related to such referral within an ongoing examination.

932 (d) Based on the findings of an examination that a pharmacy  
933 benefit manager or an applicant for authorization has exhibited  
934 a pattern or practice of knowing and willful violations of s.  
935 626.8825 or s. 626.8827, the office may, pursuant to chapter  
936 120, order a pharmacy benefit manager to file all contracts  
937 between the pharmacy benefit manager and pharmacies or pharmacy  
938 benefits plans or programs and any policies, guidelines, rules,  
939 protocols, standard operating procedures, instructions, or  
940 directives that govern or guide the manner in which the pharmacy  
941 benefit manager or applicant conducts business related to such  
942 knowing and willful violations for review and inspection for the  
943 following 36-month period. Such documents are public records and  
944 are not trade secrets or otherwise exempt from s. 119.07(1). As  
945 used in this section, the term:

946 1. "Contracts" means any contract to which s. 626.8825 is  
947 applicable.

948 2. "Knowing and willful" means any act of commission or  
949 omission which is committed intentionally, as opposed to  
950 accidentally, and which is committed with knowledge of the act's  
951 unlawfulness or with reckless disregard as to the unlawfulness  
952 of the act.

953 (e) Examinations may be conducted by an independent  
954 professional examiner under contract to the office, in which  
955 case payment must be made directly to the contracted examiner by  
956 the pharmacy benefit manager examined in accordance with the  
957 rates and terms agreed to by the office and the examiner.

10-00822D-23

20231550\_\_

958       (3) In making investigations and examinations of pharmacy  
959 benefit managers and applicants for authorization, the office  
960 and such pharmacy benefit manager is subject to all of the  
961 following provisions:

962           (a) Section 624.318, as to the conduct of examinations.

963           (b) Section 624.319, as to examination and investigation  
964 reports.

965           (c) Section 624.321, as to witnesses and evidence.

966           (d) Section 624.322, as to compelled testimony.

967           (e) Section 624.324, as to hearings.

968           (f) Section 624.34, as to fingerprinting.

969           (g) Any other provision of chapter 624 applicable to the  
970 investigation or examination of a licensee under this part.

971       (4) (a) A pharmacy benefit manager must maintain an accurate  
972 record of all contracts and records with all pharmacies and  
973 pharmacy benefits plans or programs for the duration of the  
974 contract, and for 5 years thereafter. Such contracts must be  
975 made available to the office and kept in a form accessible to  
976 the office.

977           (b) The office may order any pharmacy benefit manager or  
978 applicant to produce any records, books, files, contracts,  
979 advertising and solicitation materials, or other information and  
980 may take statements under oath to determine whether the pharmacy  
981 benefit manager or applicant is in violation of the law or is  
982 acting contrary to the public interest.

983       (5) (a) Notwithstanding s. 624.307(3), each pharmacy benefit  
984 manager and applicant for authorization must pay to the office  
985 the expenses of the examination or investigation. Such expenses  
986 include actual travel expenses, reasonable living expense

10-00822D-23

20231550\_\_

987 allowance, compensation of the examiner, investigator, or other  
988 person making the examination or investigation, and necessary  
989 costs of the office directly related to the examination or  
990 investigation. Such travel expense and living expense allowances  
991 are limited to those expenses necessarily incurred on account of  
992 the examination or investigation and shall be paid by the  
993 examined pharmacy benefit manager or applicant together with  
994 compensation upon presentation by the office to such pharmacy  
995 benefit manager or applicant of such charges and expenses after  
996 a detailed statement has been filed by the examiner and approved  
997 by the office.

998 (b) All moneys collected from pharmacy benefit managers and  
999 applicants for authorization pursuant to this subsection shall  
1000 be deposited into the Insurance Regulatory Trust Fund, and the  
1001 office may make deposits from time to time into such fund from  
1002 moneys appropriated for the operation of the office.

1003 (c) Notwithstanding s. 112.061, the office may pay to the  
1004 examiner, investigator, or person making such examination or  
1005 investigation out of such trust fund the actual travel expenses,  
1006 reasonable living expense allowance, and compensation in  
1007 accordance with the statement filed with the office by the  
1008 examiner, investigator, or other person, as provided in  
1009 paragraph (a).

1010 (6) In addition to any other enforcement authority  
1011 available to the office, the office shall impose an  
1012 administrative fine of \$5,000 for each violation of s. 626.8825  
1013 or s. 626.8827. Each instance of a violation of such sections by  
1014 a pharmacy benefit manager against each individual pharmacy or  
1015 prescription benefits plan or program constitutes a separate

10-00822D-23

20231550\_\_

1016 violation. Notwithstanding any other provision of law, there is  
1017 no limitation on aggregate fines issued pursuant to this  
1018 section. The proceeds from any administrative fine shall be  
1019 deposited into the General Revenue Fund.

1020 (7) Failure by a pharmacy benefit manager to pay expenses  
1021 incurred or administrative fines imposed under this section is  
1022 grounds for the denial, suspension, or revocation of its  
1023 certificate of authority.

1024 Section 13. Section 626.89, Florida Statutes, is amended,  
1025 to read:

1026 626.89 Annual financial statement and filing fee; notice of  
1027 change of ownership; pharmacy benefit manager filings.—

1028 (1) Each authorized administrator shall annually file with  
1029 the office a full and true statement of its financial condition,  
1030 transactions, and affairs within 3 months after the end of the  
1031 administrator's fiscal year or within such extension of time as  
1032 the office for good cause may have granted. The statement must  
1033 be for the preceding fiscal year and must be in such form and  
1034 contain such matters as the commission prescribes and must be  
1035 verified by at least two officers of the administrator.

1036 (2) Each authorized administrator shall also file an  
1037 audited financial statement performed by an independent  
1038 certified public accountant. The audited financial statement  
1039 must ~~shall~~ be filed with the office within 5 months after the  
1040 end of the administrator's fiscal year and be for the preceding  
1041 fiscal year. An audited financial statement prepared on a  
1042 consolidated basis must include a columnar consolidating or  
1043 combining worksheet that must be filed with the statement and  
1044 must comply with the following:

10-00822D-23

20231550\_\_

1045 (a) Amounts shown on the consolidated audited financial  
1046 statement must be shown on the worksheet;

1047 (b) Amounts for each entity must be stated separately; and

1048 (c) Explanations of consolidating and eliminating entries  
1049 must be included.

1050 (3) At the time of filing its annual statement, the  
1051 administrator shall pay a filing fee in the amount specified in  
1052 s. 624.501 for the filing of an annual statement by an insurer.

1053 (4) In addition, the administrator shall immediately notify  
1054 the office of any material change in its ownership.

1055 (5) A pharmacy benefit manager shall also notify the office  
1056 within 15 days after any administrative, civil, or criminal  
1057 complaints, settlements, or discipline of the pharmacy benefit  
1058 manager or any of its affiliates which relate to a violation of  
1059 the insurance laws, including pharmacy benefit laws in any  
1060 state.

1061 (6) A pharmacy benefit manager shall also annually submit  
1062 to the office a statement attesting to its compliance with the  
1063 network requirements of s. 626.8825.

1064 (7) The commission may by rule require all or part of the  
1065 statements or filings required under this section to be  
1066 submitted by electronic means in a computer-readable form  
1067 compatible with the electronic data format specified by the  
1068 commission.

1069 Section 14. Subsection (5) is added to section 627.42393,  
1070 Florida Statutes, to read:

1071 627.42393 Step-therapy protocol.—

1072 (5) This section applies to a pharmacy benefit manager  
1073 acting on behalf of a health insurer.

10-00822D-23

20231550\_\_

1074 Section 15. Subsections (2), (3), and (4) of section  
1075 627.64741, Florida Statutes, are amended to read:

1076 627.64741 Pharmacy benefit manager contracts.—

1077 (2) In addition to the requirements of part VII of chapter  
1078 626, a contract between a health insurer and a pharmacy benefit  
1079 manager must require that the pharmacy benefit manager:

1080 (a) Update maximum allowable cost pricing information at  
1081 least every 7 calendar days.

1082 (b) Maintain a process that will, in a timely manner,  
1083 eliminate drugs from maximum allowable cost lists or modify drug  
1084 prices to remain consistent with changes in pricing data used in  
1085 formulating maximum allowable cost prices and product  
1086 availability.

1087 ~~(3) A contract between a health insurer and a pharmacy~~  
1088 ~~benefit manager must prohibit the pharmacy benefit manager from~~  
1089 ~~limiting a pharmacist's ability to disclose whether the cost-~~  
1090 ~~sharing obligation exceeds the retail price for a covered~~  
1091 ~~prescription drug, and the availability of a more affordable~~  
1092 ~~alternative drug, pursuant to s. 465.0244.~~

1093 ~~(4) A contract between a health insurer and a pharmacy~~  
1094 ~~benefit manager must prohibit the pharmacy benefit manager from~~  
1095 ~~requiring an insured to make a payment for a prescription drug~~  
1096 ~~at the point of sale in an amount that exceeds the lesser of:~~

1097 ~~(a) The applicable cost sharing amount; or~~

1098 ~~(b) The retail price of the drug in the absence of~~  
1099 ~~prescription drug coverage.~~

1100 Section 16. Subsections (2), (3), and (4), of section  
1101 627.6572, Florida Statutes, are amended to read:

1102 627.6572 Pharmacy benefit manager contracts.—

10-00822D-23

20231550\_\_

1103           (2) In addition to the requirements of part VII of chapter  
1104 626, a contract between a health insurer and a pharmacy benefit  
1105 manager must require that the pharmacy benefit manager:

1106           (a) Update maximum allowable cost pricing information at  
1107 least every 7 calendar days.

1108           (b) Maintain a process that will, in a timely manner,  
1109 eliminate drugs from maximum allowable cost lists or modify drug  
1110 prices to remain consistent with changes in pricing data used in  
1111 formulating maximum allowable cost prices and product  
1112 availability.

1113           ~~(3) A contract between a health insurer and a pharmacy~~  
1114 ~~benefit manager must prohibit the pharmacy benefit manager from~~  
1115 ~~limiting a pharmacist's ability to disclose whether the cost-~~  
1116 ~~sharing obligation exceeds the retail price for a covered~~  
1117 ~~prescription drug, and the availability of a more affordable~~  
1118 ~~alternative drug, pursuant to s. 465.0244.~~

1119           ~~(4) A contract between a health insurer and a pharmacy~~  
1120 ~~benefit manager must prohibit the pharmacy benefit manager from~~  
1121 ~~requiring an insured to make a payment for a prescription drug~~  
1122 ~~at the point of sale in an amount that exceeds the lesser of:~~

1123           ~~(a) The applicable cost-sharing amount; or~~

1124           ~~(b) The retail price of the drug in the absence of~~  
1125 ~~prescription drug coverage.~~

1126           Section 17. Paragraph (e) is added to subsection (46) of  
1127 section 641.31, Florida Statutes, to read:

1128           641.31 Health maintenance contracts.—

1129           (46)

1130           (e) This subsection applies to a pharmacy benefit manager  
1131 acting on behalf of a health maintenance organization.

10-00822D-23

20231550\_\_

1132 Section 18. Subsections (2), (3), and (4) of section  
1133 641.314, Florida Statutes, are amended to read:

1134 641.314 Pharmacy benefit manager contracts.—

1135 (2) In addition to the requirements of part VII of chapter  
1136 626, a contract between a health maintenance organization and a  
1137 pharmacy benefit manager must require that the pharmacy benefit  
1138 manager:

1139 (a) Update maximum allowable cost pricing information at  
1140 least every 7 calendar days.

1141 (b) Maintain a process that will, in a timely manner,  
1142 eliminate drugs from maximum allowable cost lists or modify drug  
1143 prices to remain consistent with changes in pricing data used in  
1144 formulating maximum allowable cost prices and product  
1145 availability.

1146 ~~(3) A contract between a health maintenance organization~~  
1147 ~~and a pharmacy benefit manager must prohibit the pharmacy~~  
1148 ~~benefit manager from limiting a pharmacist's ability to disclose~~  
1149 ~~whether the cost-sharing obligation exceeds the retail price for~~  
1150 ~~a covered prescription drug, and the availability of a more~~  
1151 ~~affordable alternative drug, pursuant to s. 465.0244.~~

1152 ~~(4) A contract between a health maintenance organization~~  
1153 ~~and a pharmacy benefit manager must prohibit the pharmacy~~  
1154 ~~benefit manager from requiring a subscriber to make a payment~~  
1155 ~~for a prescription drug at the point of sale in an amount that~~  
1156 ~~exceeds the lesser of:~~

1157 ~~(a) The applicable cost-sharing amount; or~~

1158 ~~(b) The retail price of the drug in the absence of~~  
1159 ~~prescription drug coverage.~~

1160 Section 19. Subsection (1) of section 624.491, Florida



10-00822D-23

20231550\_\_

1161 Statutes, is amended to read:

1162       624.491 Pharmacy audits.—

1163       (1) A health insurer or health maintenance organization  
1164 providing pharmacy benefits through a major medical individual  
1165 or group health insurance policy or a health maintenance  
1166 contract, respectively, must comply with the requirements of  
1167 this section when the health insurer or health maintenance  
1168 organization or any person or entity acting on behalf of the  
1169 health insurer or health maintenance organization, including,  
1170 but not limited to, a pharmacy benefit manager as defined in s.  
1171 626.88 ~~s. 624.490(1)~~, audits the records of a pharmacy licensed  
1172 under chapter 465. The person or entity conducting such audit  
1173 must:

1174       (a) Except as provided in subsection (3), notify the  
1175 pharmacy at least 7 calendar days before the initial onsite  
1176 audit for each audit cycle.

1177       (b) Not schedule an onsite audit during the first 3  
1178 calendar days of a month unless the pharmacist consents  
1179 otherwise.

1180       (c) Limit the duration of the audit period to 24 months  
1181 after the date a claim is submitted to or adjudicated by the  
1182 entity.

1183       (d) In the case of an audit that requires clinical or  
1184 professional judgment, conduct the audit in consultation with,  
1185 or allow the audit to be conducted by, a pharmacist.

1186       (e) Allow the pharmacy to use the written and verifiable  
1187 records of a hospital, physician, or other authorized  
1188 practitioner, which are transmitted by any means of  
1189 communication, to validate the pharmacy records in accordance

10-00822D-23

20231550\_\_

1190 with state and federal law.

1191 (f) Reimburse the pharmacy for a claim that was  
1192 retroactively denied for a clerical error, typographical error,  
1193 scrivener's error, or computer error if the prescription was  
1194 properly and correctly dispensed, unless a pattern of such  
1195 errors exists, fraudulent billing is alleged, or the error  
1196 results in actual financial loss to the entity.

1197 (g) Provide the pharmacy with a copy of the preliminary  
1198 audit report within 120 days after the conclusion of the audit.

1199 (h) Allow the pharmacy to produce documentation to address  
1200 a discrepancy or audit finding within 10 business days after the  
1201 preliminary audit report is delivered to the pharmacy.

1202 (i) Provide the pharmacy with a copy of the final audit  
1203 report within 6 months after the pharmacy's receipt of the  
1204 preliminary audit report.

1205 (j) Calculate any recoupment or penalties based on actual  
1206 overpayments and not according to the accounting practice of  
1207 extrapolation.

1208 Section 20. (1) This act establishes requirements for  
1209 pharmacy benefit managers as defined in s. 624.490, Florida  
1210 Statutes, including, without limitation, pharmacy benefit  
1211 managers in their performance of services for or otherwise on  
1212 behalf of a pharmacy benefits plan or program providing coverage  
1213 pursuant to Titles XVIII, XIX, or XXI of the Social Security  
1214 Act, 42 U.S.C. ss. 1395 et seq., 1396 et seq., and 1397aa et  
1215 seq., known as Medicare, Medicaid, or any other similar coverage  
1216 under a state or Federal Government funded health plan,  
1217 including the Statewide Medicaid Managed Care program  
1218 established pursuant to part IV of chapter 409, Florida

10-00822D-23

20231550\_\_

1219 Statutes, and the state group insurance program pursuant to part  
1220 I of chapter 110, Florida Statutes.

1221 (2) This act is not intended, nor may it be construed, to  
1222 conflict with existing, relevant federal law.

1223 (3) If any provision of this act or its application to any  
1224 person or circumstances is held invalid, the invalidity does not  
1225 affect other provisions or applications of this act which can be  
1226 given effect without the invalid provision or application, and  
1227 to this end the provisions of this act are severable.

1228 Section 21. The sum of \$1.5 million is hereby appropriated  
1229 to the Office of Insurance Regulation to implement this act.

1230 Section 22. This act shall take effect July 1, 2023.